2024-09-21 - Analysis Report
## Abbott Laboratories (ABT) Stock Analysis

**Company Overview:** Abbott Laboratories is a global healthcare company that develops, manufactures, and markets a wide range of pharmaceutical and medical products.

**Performance Analysis:**

1. **Relative Performance:**
    * **Cumulative Return:** ABT has a cumulative return of 103.7% compared to the S&P 500 (VOO) with a return of 133.16%.
    * **Lagging Behind:** ABT is currently lagging behind the S&P 500 by 29.46%. This means that ABT has underperformed compared to the broader market, but its relative position is in the 13.14% percentile within its historical range. 
    * **Note:** While ABT has underperformed compared to the market, it's important to note that the relative underperformance is within its historical range.

2. **Recent Price Action:**
    * **Closing Price:** $113.51
    * **Moving Averages:**  
        * 5-day Moving Average: $116.0 (Slightly above the closing price, suggesting potential for upward movement)
        * 20-day Moving Average: $114.63 (Slightly above the closing price, suggesting potential for upward movement)
        * 60-day Moving Average: $108.97 (Significantly lower than the closing price, indicating potential for further price increase)

3. **Technical Indicators:**
    * **RSI:** 52.67 (Neutral, indicating neither overbought nor oversold conditions)
    * **PPO:** -0.29 (Slightly negative, indicating potential for a slowdown or slight downward trend)
    * **Relative Divergence:** -0.41 (Negative, indicating a short-term downtrend)
    * **Expected Return:** 71.39% (Represents the expected return based on current investment, suggesting potential for significant gains over 5-10 years)

4. **Recent Earnings:**
    * **Latest Earnings:**
        * **Date:** 2024-07-31
        * **EPS:** $0.74
        * **Revenue:** $10.38 Billion
        * **Expected EPS:** (Information not provided)
    * **Overall:**  ABT has consistently maintained a steady revenue stream with a slight increase in its most recent quarter. However, without the expected EPS data, it's difficult to accurately evaluate the earnings performance compared to market expectations.

**Overall Analysis:**
ABT is a large-cap healthcare company with a relatively consistent track record of revenue generation. Despite lagging behind the S&P 500 in recent years, its price action suggests potential for continued growth, particularly considering the upward trend indicated by moving averages. Technical indicators show a neutral to slightly negative outlook in the short term. The long-term expected return is promising.  A more in-depth analysis would require further research into the expected EPS and a detailed examination of the company's future growth strategies and market position. 
